Milan, 15th Sept. 2016 - Zambon SpA, the pharmaceutical company of the group Zambon, has appointed Roberto Tascione as new CEO to drive the business on a global scale.
Tascione, 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol Myers Squibb as President and Chief Executive Officer Italy. In recent years he led the arrival on the Italian market of some of the most innovative drugs , including Eviplera and Stribild for HIV, Daklinza for HCV and Opdivo in immuno – oncology. Tascione also served on the General Council of Confindustria and was member of Farmindustria Board and the Committee for the Ethical Code.
"Zambon is a leading Italian excellence, with a strong tradition and a strong international outlook dating back to the ‘50s- said Tascione- I share the same values and I am very proud to drive the company in this new stage of growth, look at new business opportunities and strengthen our international network. I have accepted this new role with great enthusiasm and commitment ".
Elena Zambon, President of Zambon Spa, commented "I believe that a company with 110 years of history needs to rethink its role in providing innovative therapeutic solutions to patients. We reconfirm a group governance with complementary roles between shareholders and management, and we are sure that Roberto Tascione with his long-standing experience in this sector will help us reach important goals. With him we share the vision of an Open Company model that makes use of the advantages of digital technologies and that puts great attention to the development of internal talent in order for them to become agents of change”.
Zambon is an Italian family company operating in the pharmaceutical and fine chemicals for 110 years with more than 2,800 employees in 19 countries in 3 continents, Europe, America and Asia. In 2015 the Group reported revenues for 670 million Euro, with 566.9 million Euro resulting from the pharmaceutical business. Founded in 1906 in Vicenza, Zambon has earned over the years a strong international reputation thanks to its high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care in addition to orphan drugs such as cystic fibrosis and treatments for the central nervous system in Parkinson's disease. Zambon manufacturing is done in Italy, Switzerland, France, Brazil and China and its products are sold in 84 countries.
For more information: www.zambongroup.com
Milva Naguib – Media Relations